Ben Goldacre - Bad Pharma (2012) mp3 Audio Book

Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients

A rip from CD, file names are useful, and well tagged.

From the Wikipedia article:

Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.

Goldacre argues in the book that "the whole edifice of medicine is broken," because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products, that it routinely withholds negative data, that trials are often conducted on small groups of unrepresentative subjects, that it funds much of doctors' continuing education, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a "murderous disaster," and makes suggestions for action by patients' groups, physicians, academics and the industry itself.

The Association of the British Pharmaceutical Industry, the trade association in the UK for pharmaceutical companies, issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.

In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.

read more...: